• Repositorio Institucional Universidad de Pamplona
  • Trabajos de pregrado y especialización
  • Facultad de Salud
  • Medicina
    • Por favor, use este identificador para citar o enlazar este ítem: http://repositoriodspace.unipamplona.edu.co/jspui/handle/20.500.12744/9158
    Registro completo de metadatos
    Campo DC Valor Lengua/Idioma
    dc.contributor.authorAparicio Veloza, Luis Alberto.-
    dc.contributor.authorArchila Tarazona, Dayana Marcela.-
    dc.contributor.authorRamón Mora, Harold Andrés.-
    dc.contributor.authorRodríguez Contreras, Angela Paola.-
    dc.date.accessioned2024-11-13T20:57:58Z-
    dc.date.available2023-02-01-
    dc.date.available2024-11-13T20:57:58Z-
    dc.date.issued2023-
    dc.identifier.citationAparicio Veloza, L. A.; Archila Tarazona, D. M.; Ramón Mora, H. A.; Rodríguez Contreras, A. P. (2022). Manejo del Covid-19: una revisión de la literatura [Trabajo de Grado Pregrado, Universidad de Pamplona]. Repositorio Hulago Universidad de Pamplona. http://repositoriodspace.unipamplona.edu.co/jspui/handle/20.500.12744/9158es_CO
    dc.identifier.urihttp://repositoriodspace.unipamplona.edu.co/jspui/handle/20.500.12744/9158-
    dc.descriptionLa pandemia reciente del COVID-19 ha dado la vuelta al globo causando una gran preocupación a nivel mundial, debido a la evidencia limitada disponible al inicio de la pandemia sobre la biología del virus y sobre la eficacia de las opciones de tratamiento disponible se ha presentado un enorme impacto en términos de morbilidad y mortalidad, así como en el impacto económico y social. El objetivo de esta monografía es el de presentar una visión general sobre esta patología de gran interés en la salud pública y referenciar las diversas opciones de tratamiento que están siendo aplicadas y estudiadas por su potencial para servir como agentes contra el SARS-CoV-2. Esta monografía se realizó mediante la revisión de los artículos más relevantes consignados con respecto al manejo del COVID-19. Se concluyó que existen, a día de hoy estrategias terapéuticas muy prometedoras para el tratamiento del COVID-19 moderado y severo, destacando entre ellas opciones de corticoides y antivirales, sin embargo el enfoque preventivo continua siendo el más costo-eficaz para luchar con la pandemia, aún más con teniendo en cuenta las múltiples opciones de vacunación que se han desarrollado e implementado como base fundamental de dicho enfoque.es_CO
    dc.description.abstractThe recent COVID-19 pandemic has circled the globe causing great concern worldwide, due to the limited evidence available at the start of the pandemic on the biology of the virus and on the efficacy of available treatment options a huge impact in terms of morbidity and mortality has been presented, as well a vast economic and social impact. The objective of this monograph is to present an overview of this pathology of great public health interest and to reference the various treatment options that are being applied and studied for their potential to serve as agents against SARS-CoV-2. This monograph was carried out by reviewing the most relevant articles consigned with respect to the management of COVID-19. It was concluded that there are, today, very promising therapeutic strategies for the treatment of moderate and severe COVID-19, highlighting among them corticosteroid and antiviral options, however the preventive approach continues to be the most cost-effective to fight against the pandemic, even more so with taking into account the multiple vaccination options that have been developed and implemented as the fundamental basis of this approach.es_CO
    dc.format.extent61es_CO
    dc.format.mimetypeapplication/pdfes_CO
    dc.language.isoeses_CO
    dc.publisherUniversidad de Pamplona - Facultad de Salud.es_CO
    dc.subjectCOVID-19.es_CO
    dc.subjectSARS-COV-2.es_CO
    dc.subjectVentilación.es_CO
    dc.subjectCorticosteroides.es_CO
    dc.subjectAgentes antivirales.es_CO
    dc.titleManejo del Covid-19: una revisión de la literatura.es_CO
    dc.typehttp://purl.org/coar/resource_type/c_7a1fes_CO
    dc.date.accepted2022-11-01-
    dc.relation.referencesOtoya-Tono AM, García M, Jaramillo-Moncayo C, Willis C, Campos AM. COVID-19: generalidades, comportamiento epidemiológico y medidas adoptadas en medio de la pandemia en Colombia. Acta de Otorrinolaringología& Cirugía de Cabeza y Cuello. 2020; E-Boletín: p. 4-13.es_CO
    dc.relation.referencesWang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223): p. 470–473.es_CO
    dc.relation.referencesTang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. 2020; 16(5): p. e1008536.es_CO
    dc.relation.referencesPerlman S. Another Decade, Another Coronavirus. N Engl J Med. 2020; 382(8): p. 760– 762.es_CO
    dc.relation.referencesRecalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020; 34(5): p. e212-e213.es_CO
    dc.relation.referencesWorld Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. [Online].; 2020. Acceso 13 de 08 de 2021. Disponible en: HYPERLINK "https://www.who.int/directorgeneral/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingon-covid-19---11-march-2020" https://www.who.int/directorgeneral/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingon-covid-19---11-march-2020.es_CO
    dc.relation.referencesMcIntosh K, Hirsch MS, Bloom A. COVID-19: Epidemiology, virology, and prevention - UpToDate. [Online].; 2021. Acceso 14 de 09 de 2021. Disponible en: HYPERLINK "https://www.uptodate.com/contents/covid-19-epidemiology-virology-andprevention?topicRef=127429&source=see_link" https://www.uptodate.com/contents/covid-19-epidemiology-virology-andprevention?topicRef=127429&source=see_link .es_CO
    dc.relation.referencesMaria N, Zaid A, Catrin S, Ahmed K, Ahmed AJ, Christos I, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. International Journal of Surgery. 2020; 78: p. 185-193.es_CO
    dc.relation.referencesSánchez-Linares V, Nieda-Rosales L, Martínez-Cuervo JJ. Manifestaciones cutáneas de Covid-19. Gaceta Médica Espirituana. 2020; 22(3): p. 18-26.es_CO
    dc.relation.referencesPeters AW, Chawla KS, Turnbull ZA. Transforming ORs into ICUs. N Engl J Med. 2020; 7(382): p. (19):e52.es_CO
    dc.relation.referencesLoeb R, London MJ. Coronavirus disease 2019 (COVID-19): Intensive care ventilation with anesthesia machines. [Online].; 2020. Acceso 10 de Octubre de 2020. Disponible en: HYPERLINK "https://www-uptodate-com.aure.unab.edu.co/contents/coronavirusdisease-2019-covid-19-intensive-care-ventilation-with-anesthesiamachines?search=Covid%20mechanical%20ventilation&source=search_result&selected Title=3~150&usage_type=default&display_rank=3" https://www-uptodatecom.aure.unab.edu.co/contents/coronavirus-disease-2019-covid-19-intensive-careventilation-with-anesthesiamachines?search=Covid%20mechanical%20ventilation&source=search_result&selected Title=3~150&usage_type=default&display_rank=3.es_CO
    dc.relation.referencesZhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229).es_CO
    dc.relation.referencesThachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5).es_CO
    dc.relation.referencesDay M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020; 368(m1086).es_CO
    dc.relation.referencesRinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020; 26(9).es_CO
    dc.relation.referencesLund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, Støvring H, Johansen NB, Brun NC, Hallas J, Pottegård A. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARSCoV-2: A Danish nationwide cohort study. PLoS Med. 2020; 17(9).es_CO
    dc.relation.referencesWong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, For. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021; 80(7).es_CO
    dc.relation.referencesChandan JS, Zemedikun DT, Thayakaran R, Byne N, Dhalla S, Acosta-Mena D, Gokhale KM, Thomas T, Sainsbury C, Subramanian A, Cooper J, Anand A, Okoth KO, Wang J, Adderley NJ, Taverner T, Denniston AK, Lord J, Thomas GN, Buckley CD, Raza K, Bhala N, Nirantha. Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID- 19. Arthritis Rheumatol. 2021; 73(5).es_CO
    dc.relation.referencesDrake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, Hardwick HE, Docherty AB, Thwaites RS, Openshaw PJM, Baillie JK, Harrison EM, Semple MG, ISARIC4C Investigators. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol. 2021; 3(7).es_CO
    dc.relation.referencesGandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020; 383(18).es_CO
    dc.relation.referencesWang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3).es_CO
    dc.relation.referencesWibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson BE, de Oliveira T, Vermeulen M, van der Berg K, Rossouw T, Boswell M, Ueckermann V, Meiring S, von Gottberg A, Cohen C, Morris L, Bhiman JN, Moore PL. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; 27(4).es_CO
    dc.relation.referencesBeigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC,Ohmagari N, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19).es_CO
    dc.relation.referencesGoldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020; 383(19).es_CO
    dc.relation.referencesSpinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11).es_CO
    dc.relation.referencesZhang R, Mylonakis E. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for inhospital mortality. Ann Intern Med. 2021; 174(2).es_CO
    dc.relation.referencesRECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 383(21).es_CO
    dc.relation.referencesBoulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Et. al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020; 383(6).es_CO
    dc.relation.referencesMitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, Tobias A, Peñafiel J, Ballana E, Pérez CA, Admella P, Riera-Martí N, Laporte P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Cuatrecasas G, Cañadas P, Et. al. A ClusterRandomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med. 2021; 384(5).es_CO
    dc.relation.referencesCao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Et. Al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19).es_CO
    dc.relation.referencesCaly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178(104787).es_CO
    dc.relation.referencesLópez-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, Díazgranados JA, Oñate JM, Chavarriaga H, Herrera S, Parra B, Libreros G, Jaramillo R, Avendaño AC, Toro DF, Torres M, Lesmes MC, Rios CA, Caicedo I. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021; 325(14).es_CO
    dc.relation.referencesWang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021; 593(7857).es_CO
    dc.relation.referencesJoyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA, Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, van Helmond N, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge DO, Et. al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv. 2020.es_CO
    dc.relation.referencesJoyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, Wiggins CC, Senefeld JW, Klompas AM, Hodge DO, Shepherd JRA, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Et. al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clin Proc. 2020; 95(9).es_CO
    dc.relation.referencesSimonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez MDL, Gamarnik AV, Ojeda DS, Santoro DM, Camino PJ, Antelo S, Rainero K, Vidiella GP, Miyazaki EA, Cornistein W, Trabadelo OA, Et. al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021; 384(7).es_CO
    dc.relation.referencesLi L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(5).es_CO
    dc.relation.referencesConvalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020; 371(m4232).es_CO
    dc.relation.referencesBaum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, Ni M, Wei Y, Mohammadi K, Musser B, Atwal GS, Oyejide A, Goez-Gazi Y, Dutton J, Clemmons E, Staples HM, Bartley C, Klaffke B, Alfson K, Gazi M, Gonzalez O, Dick E, Carrion R, Pessaint L, Et. al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020; 370(6520).es_CO
    dc.relation.referencesWeinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Et. al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021; 384(3).es_CO
    dc.relation.referencesGottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Et. Al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021; 325(7).es_CO
    dc.relation.referencesWang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. bioRxiv. 2021; 12.es_CO
    dc.relation.referencesRECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Et. al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021; 384(8).es_CO
    dc.relation.referencesJiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020). Trends Immunol. 2020; 41(6).es_CO
    dc.relation.referencesRanieri VM, Pettilä V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D, Mancebo J, Ferrer R, Mercat A, Patroniti N, Quintel M, Vincent JL, Okkonen M, Meziani F, Bellani G, MacCallum N, Creteur J, Kluge S, Artigas-Raventos A, Maksimow M, Piippo I, Et. al. Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2020; 323(8).es_CO
    dc.relation.referencesMonk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP, Clark T, Djukanovic R, Wilkinson TMA. Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Respir Med. 2021; 9(2).es_CO
    dc.relation.referencesInternational Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. [Online]; 2020. Acceso 18 de 09de 2021. Disponible en: HYPERLINK "https://ish-world.com/news/a/A-statement-from-the-InternationalSociety-of-Hypertension-on-COVID-19/" https://ish-world.com/news/a/A-statementfrom-the-International-Society-of-Hypertension-on-COVID-19/.es_CO
    dc.relation.referencesDavoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother. 2020; 64(9).es_CO
    dc.relation.referencesHuet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache JM, Bézie Y, Laplanche S, Le Berre A, Le Pavec J, Salmeron S, Emmerich J, Mourad JJ, Chatellier G, Hayem G. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020; 2(7).es_CO
    dc.relation.referencesCellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging. 2020; 101(5).es_CO
    dc.relation.referencesMichot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, Balleyguier C, Besse B, Marabelle A, Netzer F, Merad M, Robert C, Barlesi F, Gachot B, Stoclin A. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 2020; 31(7).es_CO
    dc.relation.referencesRosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Et. al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021; 384(16).es_CO
    dc.relation.referencesStone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Et. al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383(24).es_CO
    dc.relation.referencesREMAP-CAP Investigators. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Et. al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16).es_CO
    dc.relation.referencesLescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N, Hagino O., Sarilumab COVID-19 Global Study Group. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021; 9(5).es_CO
    dc.relation.referencesRichardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395.es_CO
    dc.relation.referencesStebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID- 19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020; 20(4).es_CO
    dc.relation.referencesEuropean Society of Hypertension. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. [Online]; 2020. Acceso 30 de 08de 2021. Disponible en: HYPERLINK "https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/positionstatement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang" https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/positionstatement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.es_CO
    dc.relation.referencesKalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Et. al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.. N Engl J Med. 2021; 384(9).es_CO
    dc.relation.referencesCao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020; 146(1).es_CO
    dc.relation.referencesRoschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, Roshon M, Wrzesinski SH, Desai JV, Zarakas MA, Collen J, Rose K, Hamdy A, Izumi R, Wright GW, Chung KK, Baselga J, Staudt LM, Wilson WH. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020; 5(48).es_CO
    dc.relation.referencesAmerican Heart Association. Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology. Patients taking ACEi and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. [Online]; 2020. Acceso 10 de 09de 2021. Disponible en: HYPERLINK "https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-whocontract-covid-19-should-continue-treatment-unless-otherwise-advised-by-theirphysician" https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-whocontract-covid-19-should-continue-treatment-unless-otherwise-advised-by-theirphysician.es_CO
    dc.relation.referencesEuropean Society of Hypertension. ESH Statement on COVID-19. [Online]; 2020. Acceso 10 de 10de 2021. Disponible en: HYPERLINK "https://www.eshonline.org/spotlights/esh-statement-on-covid-19/" https://www.eshonline.org/spotlights/esh-statement-on-covid-19/.es_CO
    dc.relation.referencesDaniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, Ren J, Longhurst CA, Criqui MH, Messer K. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am J Cardiol. Dec; 136.es_CO
    dc.relation.referencesZhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, Lei F, Chen MM, Yang H, Bai L, Song X, Lin L, Xia M, Zhou F, Zhou J, She ZG, Zhu L, Ma X, Xu Q, Ye P, Chen G, Liu L, Mao W, Yan Y, Xiao B, Lu Z, Peng G, Liu M, Yang J, Yang L, Zhang C, Lu H, Et. al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020; 32(2).es_CO
    dc.relation.referencesRosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With InHospital Mortality in a US National Sample of Patients With COVID-19. JAMA Netw Open. 2020; 3(12).es_CO
    dc.relation.referencesPal R, Banerjee M, Yadav U, Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgrad Med J. 2021; 4.es_CO
    dc.relation.referencesYuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio. 2015; 6(4).es_CO
    dc.relation.referencesOsborne TF, Veigulis ZP, Arreola DM, Mahajan SM, Röösli E, Curtin CM. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS One. 2021; 16(2).es_CO
    dc.relation.referencesNi YN, Luo J, Yu H, Liu D, Liang BM, Liang ZA. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. Am J Emerg Med. 2018; 36(2).es_CO
    dc.relation.referencesHui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, Gin T, Chan MTV. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J.. 2019; 53(4).es_CO
    dc.relation.referencesFullick J, Oliver M. “Water, water, everywhere”: a challenge to ventilators in the COVID- 19 pandemic. Br J Anaesth. 2020; 125(1): p. e188–e190.es_CO
    dc.relation.referencesGrieco DL, Menga LS, Cesarano M, Rosà T, Spadaro S, Bitondo MM, Montomoli J, Falò G, Tonetti T, Cutuli SL, Pintaudi G, Tanzarella ES, Piervincenzi E, Bongiovanni F, Dell'Anna AM, Delle Cese L, Berardi C, Carelli S, Bocci MG, Montini L, Bello G, Et. al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. JAMA. 2021; 325(17).es_CO
    dc.relation.referencesBerlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020; 383(25).es_CO
    dc.relation.referencesCook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetist. Anaesthesia. 2020; 75(6).es_CO
    dc.relation.referencesAnesi GL, Manaker S, Finlay G, Bloom A. COVID-19: Management of the intubated adult. [Online].; 2021. Acceso 10 de 10 de 2021. Disponible en: HYPERLINK "https://www.uptodate.com/contents/covid-19-management-of-the-intubated-adult" https://www.uptodate.com/contents/covid-19-management-of-the-intubated-adult.es_CO
    dc.relation.referencesAnesi GL, Manaker S, Bloom A, Finlay G. COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation). [Online].; 2021. Acceso 10 de 10 de 2021. Disponible en: HYPERLINK "https://www.uptodate.com/contents/covid-19-respiratory-care-of-the-nonintubatedhypoxemic-adult-supplemental-oxygen-noninvasive-ventilation-and-intubation" https://www.uptodate.com/contents/covid-19-respiratory-care-of-the-nonintubatedhypoxemic-adult-supplemental-oxygen-noninvasive-ventilation-and-intubation.es_CO
    dc.relation.referencesAlhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, Et. al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020; 48(6).es_CO
    dc.relation.referencesWorld Health Organization. WHO Coronavirus (COVID-19) Dashboard. [Online].; 2021. Acceso 22 de Jun de 2021. Disponible en: HYPERLINK "https://covid19.who.int/" https://covid19.who.int/.es_CO
    dc.relation.referencesPolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Et. al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27).es_CO
    dc.relation.referencesFood And Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine. [Online]; 2021. Acceso 10 de 10de 2021. Disponible en: HYPERLINK "https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019- covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine" https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019- covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine.es_CO
    dc.relation.referencesBaden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Et. al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5).es_CO
    dc.relation.referencesBhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Gallagher J, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America. [Online].; 2021. Acceso 18 de 09 de 2021. Disponible en: HYPERLINK "https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-andmanagement/" https://www.idsociety.org/practice-guideline/covid-19-guidelinetreatment-and-management/.es_CO
    dc.relation.referencesStewart J. Moderna COVID-19 Vaccine FDA Approval Status. [Online]; 2021. Acceso 10 de 10de 2021. Disponible en: HYPERLINK "https://www.drugs.com/history/moderna-covid-19-vaccine.html" https://www.drugs.com/history/moderna-covid-19-vaccine.html .es_CO
    dc.relation.referencesSadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Et. al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23).es_CO
    dc.relation.referencesVoysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, ColinJones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Et. al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269).es_CO
    dc.relation.referencesShinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de Oliveira T, Lombard Koen A, Et. al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20).es_CO
    dc.relation.referencesCOVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021; 47(1).es_CO
    dc.relation.referencesCascella M, Rajnik M, Aleem A, Scott DC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19) - StatPearls. [Online].; 2021. Acceso 15 de 9 de 2021. Disponible en: HYPERLINK "https://www.ncbi.nlm.nih.gov/books/NBK554776/" https://www.ncbi.nlm.nih.gov/books/NBK554776/.es_CO
    dc.relation.referencesWorld Health Organization. Tracking SARS-CoV-2 variants. [Online].; 2021. Acceso 28 de June de 2021. Disponible en: HYPERLINK "https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/" https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.es_CO
    dc.relation.referencesAhmad FB, Cisewski JA, Miniño A, Anderson RN. Provisional Mortality Data - United States, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(14): p. 519-522.es_CO
    dc.relation.referencesStokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, Suad El Burai F, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(24): p. 759-765.es_CO
    dc.relation.referencesGebhard C, Vera RZ, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020; 11(29): p. doi: 10.1186/s13293- 020-00304-9.es_CO
    dc.relation.referencesJin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020; 29(8): p. doi: 10.3389/fpubh.2020.00152.es_CO
    dc.relation.referencesFinelli L, Gupta V, Tanaz P, Yu K, Bauer KA, Puzniak LA. Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020. JAMA Netw Open. 2021; 4(4): p. e216556. doi: 10.1001/jamanetworkopen.2021.6556.es_CO
    dc.relation.referencesRomano SD, Blackstock AJ, Taylor EV, El Burai Felix , Adjei S, Singleton CM, et al. Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region United States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(15).es_CO
    dc.relation.referencesSze S, Pan D, Nevill CR, Gray LJ, Martin CA, Nazareth J, Minhas JS, Divall P, Khunti K, Abrams KR, Nellums LB, Pareek M. Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2020; 29(100630).es_CO
    dc.relation.referencesHeslin KC, Hall JE. Sexual Orientation Disparities in Risk Factors for Adverse COVID- 19-Related Outcomes, by Race/Ethnicity - Behavioral Risk Factor Surveillance System, United States, 2017-2019. MMWR Morb Mortal Wkly Rep. 2021; 70(5).es_CO
    dc.relation.referencesChan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1).es_CO
    dc.relation.referencesLei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antiviral Res. 2018; 149.es_CO
    dc.relation.referencesSong W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018; 14(8).es_CO
    dc.relation.referencesJiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020; 41(5).es_CO
    dc.relation.referencesDu L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7(3).es_CO
    dc.relation.referencesde Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Laredo L, Laosa O, Centeno-Soto GA, Ángeles Gálvez M, Puerro M, González-Rojano E, Pedraza L, de Pablo I, Abad-Santos F, Rodríguez-Mañas L, Gil M, Tobías A, Et. al. MED-ACE2-COVID19 study group. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020; 395(10238).es_CO
    dc.relation.referencesXu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020; 12(1).es_CO
    dc.relation.referencesHoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2).es_CO
    dc.relation.referencesWang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020; 108(1).es_CO
    dc.relation.referencesAzkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, O'Mahony L, Gao Y, Nadeau K, Akdis CA. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020; 75(7).es_CO
    dc.relation.referencesTeuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020; 20(7).es_CO
    dc.relation.referencesAckermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2021; 383(2).es_CO
    dc.relation.referencesvan de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Brüggemann RJ, van der Hoeven H. Kallikrein-kinin blockade in patients with COVID- 19 to prevent acute respiratory distress syndrome. Elife. 2020; 9.es_CO
    dc.relation.referencesConti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020; 34(2).es_CO
    dc.relation.referencesCoopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, Hellman J, Jog S, Kesecioglu J, Kissoon N, Martin-Loeches I, Nunnally ME, Prescott HC, Rhodes A, Talmor D, Tissieres P, De Backer D. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med. 2021; 49(4).es_CO
    dc.relation.referencesMartinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV- 2?. Am J Physiol Renal Physiol. 2020; 318(6).es_CO
    dc.relation.referencesHirsch JS, Ng JH, Ross DW,Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, Jhaveri KD. Northwell COVID-19 Research Consortium. Northwell Nephrology COVID- 19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020; 98(1).es_CO
    dc.relation.referencesGupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Et. al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020; 26(7).es_CO
    dc.relation.referencesHessami A, Shamshirian A, Heydari K, Pourali F, Alizadeh-Navaei R, Moosazadeh M, Abrotan S, Shojaie L, Sedighi S, Shamshirian D, Rezaei N. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. Am J Emerg Med. 2021; 46.es_CO
    dc.relation.referencesTariq R, Saha S, Furqan F, Hassett L, Pardi D, Khanna S. Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Metaanalysis. Mayo Clin Proc. 2020; 95(8).es_CO
    dc.relation.referencesZubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol. 2020; 77(8).es_CO
    dc.relation.referencesDaneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am J Clin Dermatol. 2020; 21(5).es_CO
    dc.relation.referencesNational Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. [Online].; 2021. Acceso 27 de 08 de 2021. Disponible en: HYPERLINK "https://covid19treatmentguidelines.nih.gov/" https://covid19treatmentguidelines.nih.gov/.es_CO
    dc.relation.referencesKim AY, Gandhi RT, Hirsch MS, Bloom A. COVID-19: Management in hospitalized adults - UpToDate. [Online].; 2021. Acceso 27 de 09 de 2021. Disponible en: HYPERLINK "https://www.uptodate.com/contents/covid-19-management-inhospitalized-adults" https://www.uptodate.com/contents/covid-19-management-inhospitalized-adults.es_CO
    dc.relation.referencesWang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11).es_CO
    dc.relation.referencesGuan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18).es_CO
    dc.relation.referencesWu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(20).es_CO
    dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2es_CO
    dc.type.coarversionhttp://purl.org/coar/resource_type/c_2df8fbb1es_CO
    Aparece en las colecciones: Medicina

    Ficheros en este ítem:
    Fichero Descripción Tamaño Formato  
    Aparicio_Archila_Ramón_Rodríguez_2022_TG.pdfAparicio_Archila_Ramón_Rodríguez_2022_TG491,36 kBAdobe PDFVisualizar/Abrir
    Mostrar el registro sencillo del ítem


    Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.